Journal Article Ahead of print
PubMed: 41998762 DOI: 10.1186/s40364-026-00922-2
Genome-wide biomarker analysis across the full spectrum of HER2-expressing breast cancers to reveal a clonal chromosome 17 imbalance defining unfavourable HER2-low disease.
Biomark Res
Authors: Sara Erika Bellomo, Enrico Berrino, Pamela Arcella, Anita Chesta, Caterina Parlato, Simonetta Guarrera, Laura Casorzo, Ivana Sarotto, Mara Panero, Andrea Botticelli, Riccardo Ponzone, Pierfranco Conte, Nicola Crosetto, Anna Sapino, Caterina MarchiĆ²
Affiliations
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
- Department of Medical Sciences, University of Turin, Turin, Italy.
- IIGM-Italian Institute for Genomic Medicine, c/o IRCCS, Candiolo, TO, Italy.
- Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
- San Camillo Hospital IRCCS, Venezia, Italy.
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, 17177, Sweden.
- Science for Life Laboratory, Stockholm, Sweden.
- Human Technopole, Milan, Italy.
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
- Department of Medical Sciences, University of Turin, Turin, Italy.
MeSH
Breast Neoplasms, Genome, Biomarkers, Breast, Chromosomes, Human, Pair 17, Chromosomes